Annexon, Inc. (ANNX)
Pre-Market:
| Previous Close | 4.4400 |
| Open | 4.8200 |
| Bid | 4.4100 x 300 |
| Ask | 4.4700 x 300 |
| Day's Range | 4.4100 - 4.8500 |
| 52 Week Range | 1.5700 - 8.4000 |
| Volume | |
| Avg. Volume | 1,626,427 |
| Market Cap | 400.614M |
| Beta (5Y Monthly) | 1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7700 |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.60 |
ZacksAre Medical Stocks Lagging Annexon (ANNX) This Year?
Here is how Annexon, Inc. (ANNX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
GlobeNewswireAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on April 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). In the ag
GlobeNewswireTurnstone Biologics Appoints William Waddill to its Board of Directors
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member o
